Re: Wells et al.: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial (Ophthalmology 2016;123:1351-1359).

Related Articles

Re: Wells et al.: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial (Ophthalmology 2016;123:1351-1359).

Ophthalmology. 2017 01;124(1):e5

Authors: Shanmugam MP, Harshey KB, Ramanjulu R, Mishra DK

PMID: 27993278 [PubMed - indexed for MEDLINE]

from #PM All via ola Kala on Inoreader https://ift.tt/2IitpQs